Binding of Hypoglycaemic Sulphonylureas to an Artificial Phospholipid Bilayer

Total Page:16

File Type:pdf, Size:1020Kb

Binding of Hypoglycaemic Sulphonylureas to an Artificial Phospholipid Bilayer Diabetologia (1984) 26:55-59 Diabetologia @ Springer-Verlag 1984 Binding of hypoglycaemic sulphonylureas to an artificial phospholipid bilayer M. Deleers and W.J. Malaisse Laboratory of Experimental Medicine, Brussels University Medical School, Brussels, Belgium Summary. Hypoglycaemic sulphonylureas bind to multilamel- gogues. It is proposed that the insertion of hypoglycaemic lar liposomes formed of egg yolk phosphatidylcholine. In this sulphonylureas into the phospholipid domain of the B cell artificial model, both specific and non-specific components of membrane could represent a primary event in the mechanism the binding phenomenon can be characterized by the same by which these agents stimulate insulin release. criteria as those used in studies performed with natural mem- branes. The relative ability of distinct sulphonylureas to inhib- Key words: Liposomes, phospholipid, hypoglycaemic sul- it the binding of 3H-glibenclamide or 3H-gliquidone to the lip- phonylurea, glibenclamide, gliquidone, gliclazide, tolbut- osomes parallels their relative potency as insulin secreta- amide, chlorpropamide. Hypoglycaemic sulphonylureas stimulate insulin re- glibenclamide and tolbutamide were obtained from Hoechst, gliqui- lease, apparently by facilitating the inflow of Ca 2+ into done from Thomae, gliclazide from Servier Benelux, Brussels, Bel- the pancreatic B cell [1, 21. Most authors favour the view gium and chlorpropamide from Pfizer, Brussels, Belgium. Multilamellar liposomes of egg yolk phosphatidylcholine were that the stimulation of Ca 2+ inflow is secondary to a de- formed as described elsewhere [13] in a Tris-HCl buffer (50 retool/l, crease in K + conductance, leading to depolarization of pH 7.30) yielding a final concentration of 2 mg/ml. The sulphonyl- the plasma membrane and gating of voltage-sensitive ureas were added to this buffer from stock solutions prepared in a calcium channels [3-6]. The molecular mechanism re- mixture of ethanol and 0.1 N NaOH (1/1, v/v), the final concentra- tion of these solvents not exceeding 0.2% (v/v). Aliquots (0.25 ml) of sponsible for the change in K § permeability is not the liposomal suspension were placed in polyethylene microcentri- known [7]. Radioisotopic studies of sulphonylurea up- fuge tubes (Beckman, Palo Alto, California, USA), incubated for 5-60 take by isolated islets suggest that these hypoglycaemic min at 37~ and centrifuged for 30min at 4~ and 3,000 g. The su- agents are bound to the plasma membrane of pancreatic pernatant solution was then removed and the bottom of the tube con- B cells [8-10], which could be equipped with sulphonyl- taining the pellet of liposomes cut, placed in a counting vial contain- ing 6 ml of scintillation fluid (Aquasol-2; New England Nuclear, Bos- urea receptors [111. The cell boundary [12] could there- ton, Massachusetts, USA), and eventually examined for its radio- fore represent the primary site of action of hypoglycae- active content. mic sulphonylureas. The specific radioactivity of 3H-glibenclamide or 3H-gliquidone The aim of the present study was to investigate how was kept unchanged in all experiments, except for measurement of the non-specific binding in which case unlabelled sulphonylurea was far the binding of sulphonylureas to natural membranes added at a final concentration of 0.1 mmol/l. Such a non-specific could be simulated in an artificial model of phospho- binding was measured for each condition under study. Results are ex- lipid bilayer. pressed as mean + SEM values together with the numbers of individu- al determinations (n). Materials and methods Results Egg yolk phosphatidylcholine was purchased from Sigma (St. Louis, Missouri, USA). 3H-glibenclamide (31.1 Ci/mmol) was kindly pro- At a 20 nmol/1 concentration of 3H-gliquidone, the ap- vided by M.H. Mertens (Hoechst Belgium, Brussels, Belgium), and parent binding of the sulphonylurea to the liposomes 3H-gliquidone (4.8 Ci/mmol) by Dr N. Kaubisch (Boehringer, Ingel- beim, FRG) and Dr Rupprecht (Thomae, Biberach, FRG). Both sul- reached an equilibrium value within 15 min of exposure phonylureas were tritiated in the cyclohexyl ring and their purity as- to the drug (Figure 1). At the same concentration of the sessed by chromatographic analysis to be >96%. Unlabelled radioactive compound but in the presence of a much 56 M. Deleers and W. J. Malaisse: Binding of hypoglycaemic sulphonylureas higher concentration of unlabelled gliquidone (0.1 sumed to represent the non-specific binding, it should be retool/l), the radioactivity associated with the lipo- substracted from other readings in order to characterize somes also rapidly reached equilibrium. Further experi- the specific binding of 3H-sulphonylurea. In a range of ments were performed over 30 rain incubation. concentrations from 0.2 to 10.0-15.0 nmol/1, such a spe- In experiments performed in the presence of a cific binding was not quite proportional to the drug 10nmol/1 concentration of 3H-sulphonylurea and a concentration (Fig. 2), the specific binding recorded at 0.1 mmol/1 concentration of the unlabelled drug, the to- the highest concentration amounting to only 63% (glib- tal binding of glibenclamide and gliquidone averaged enclamide) and 77% (gliquidone) of the theoretical val- 13.3 + 0.7 and 28.2 + 0.9 nmol/mg of phospholipid, re- ues obtained by linear extrapolation of the data collect- spectively (n = 6-10). This corresponds to approximate- ed at the four lowest concentrations of sulphonylurea ly 1.00_+ 0.05 and 2.12+ 0.07 tool sulphonylurea/100 (i. e. between 0.2 and 2.0 nmol/1). mol phospholipid. If the binding of 3H-sulphonylurea Figure 3 illustrates the effect of increasing concen- at this high concentration of the unlabelled agent is as- trations of unlabelled gliquidone and gliclazide upon the specific binding of 3H-glibenclamide (10.0 nmol/1). Within the range of concentrations under investigation (10.0 nmol/1 to 0.] mmol/1), the binding of 3H-gliben- 2O clamide was much more severely inhibited by gliqui- E done than by gliclazide. Tolbutamide also slightly de- creased 3H-glibenclamide binding (p<0.01), whereas '? 16 0 chlorpropamide failed to affect 3H-glibenclamide bind- E ing significantly (p> 0.1; data not shown). ,~,12 The inhibition of 3H-gliquidone-specific binding by unlabelled sulphonylureas is illustrated in Figure 4. The three drugs tested, namely gliclazide, tolbutamide, and "ID C chlorpropamide, all caused significant inhibition. The "~ 8 slopes of the regression lines for the inhibitory effect o "o were not vastly different from one another. However, o" 4 the concentrations of sulphonylurea required to cause 50% inhibition of 3H-gliquidone-specific binding i "r spanned a range of at least two orders of magnitude, av- o I i eraging 0.6 lxmol/1 with gliclazide, 6.4 .Ltmo1/l with tol- o 5 lJO 1~5 2 0 // ;0 butamide and 0.1 retool/1 with chlorpropamide. Crn,n) Fig.l. Time course for the total ( and non-specific ( .... binding of 3H-gliquidone (20 nmol/1) to liposomes as mea- Discussion sured in the absence and presence of unlabelled gliquidone (0.1 mmol/1), respectively. Mean _+ SEM values refer to four individu- In this study we have investigated the binding of hypo- al determinations and are expressed as cpm. 10-3/rag phospholipid. glycaemic sulphonylureas to liposomes formed of egg 0.8 0.8 /// E ////~ --~" 0.6 0.6 o E // E / O / / E + "t] .c 0.4 /// .E O4 /// "1:] //I E Fig. 2. Relationship between concentration and specif- g ic binding of 3H-glibenclamide and 3H-gliquidone to ~: 0.2 ~ 0.2 / liposomes. Mean + SEM values refer to six to ten indi- ._g vidual determinations and are expressed as pmol sul- o phonylurea bound/mg phospholipid. The dotted lines 4- illustrate relationships of proportionality with a slope ( o derived from the data collected at the four lowest con- centrations of sulphonylurea (0.2-2.0 nmol/1) O ; I'O 0 0 GL,BENCLAMIDE Gmoil0 GLIQUIDONE ~mol/b M. Deleers and W. J. Malaisse: Binding of hypoglycaemic sulphonylureas 57 100 o as the liposome-associated radioactivity represented 34%-64% of the total radioactivity present in each sam- o o o ple. Three major analogies can be found between the 80 present results and those obtained with natural mem- MJo~ branes. First, in our system just as in brain membranes [11] r "0 or intact islets [15-17], the total binding of [3H] sulpho- " 6C nylurea increased progressively, albeit not proportion- ally, as the concentration of sulphonylurea was raised in "0 a range between 0.2 nmol/1 and 0.1 mmol/1. At the lat- E "2. ter concentration, the equilibrium value for total bind- -~u 40 c ing to intact islets averaged 0.15, 0.67 and 3.15 mmol/kg 0~ .Q dry weight in the case of tolbutamide [15], glibornuride [16] and glibenclamide [17], respectively. If these values ~ 20 -1- are representative of binding to the plasma membrane, as proposed by the Ume5 group, they would corre- spond, in the case of glibenclamide, to a sulphonylurea/ 0 i i I i i phospholipid molar ratio close to unity. This estimation 10-8 10-7 10-6 10-5 10-4 is based on the knowledge that, in pancreatic islets, SULPHONYLUREA (m o,/,) the plasma membrane/dry weight ratio is close to Fig.3. Inhibition of the specific binding of 3H-glibenclamide 1700 m2/kg dry weight [18, 19] and that the content in (10 nmol/1) to liposomes by increasing concentrations of unlabelled phospholipids (averaged molecular weight taken as gliquidone (0-----0) or gliclazide (O O). Each value refers to 750) of biological membranes is close to 1.4 mg/m 2 [20, the point-moving mean derived from quintuplate measurements per- 21]. However, if the hypoglycaemic sulphonylureas formed at each concentration of sulphonylurea.
Recommended publications
  • Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity
    molecules Review Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity Babiker M. El-Haj 1,* and Samrein B.M. Ahmed 2 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, Fufairah 00971, UAE 2 College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah 00971, UAE; [email protected] * Correspondence: [email protected] Received: 6 February 2020; Accepted: 7 April 2020; Published: 22 April 2020 Abstract: Alkyl moieties—open chain or cyclic, linear, or branched—are common in drug molecules. The hydrophobicity of alkyl moieties in drug molecules is modified by metabolic hydroxy functionalization via free-radical intermediates to give primary, secondary, or tertiary alcohols depending on the class of the substrate carbon. The hydroxymethyl groups resulting from the functionalization of methyl groups are mostly oxidized further to carboxyl groups to give carboxy metabolites. As observed from the surveyed cases in this review, hydroxy functionalization leads to loss, attenuation, or retention of pharmacologic activity with respect to the parent drug. On the other hand, carboxy functionalization leads to a loss of activity with the exception of only a few cases in which activity is retained. The exceptions are those groups in which the carboxy functionalization occurs at a position distant from a well-defined primary pharmacophore. Some hydroxy metabolites, which are equiactive with their parent drugs, have been developed into ester prodrugs while carboxy metabolites, which are equiactive to their parent drugs, have been developed into drugs as per se.
    [Show full text]
  • Actions of Glucagon-Like Peptide-1 on KATP Channel-Dependent and -Independent Effects of Glucose, Sulphonylureas and Nateglinide
    889 Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide Neville H McClenaghan1, Peter R Flatt1 and Andrew J Ball1,2 1School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK 2Chemicon International Inc., 28820 Single Oak Drive, Temecula, California 92590, USA (Requests for offprints should be addressed to A J Ball; Email: [email protected]) Abstract This study examined the effects of glucagon-like peptide-1 PKA and PKC downregulation, indicating that GLP-1 can (GLP-1) on insulin secretion alone and in combination with modulate KATP channel-independent insulin secretion by sulphonylureas or nateglinide, with particular attention to KATP protein kinase-dependent and -independent mechanisms. The channel-independent insulin secretion. In depolarised cells, synergistic insulin-releasing effects of combinatorial GLP-1 and GLP-1 significantly augmented glucose-induced KATP sulphonylurea/nateglinide were lost following PKA- or PKC- channel-independent insulin secretion in a glucose concen- desensitisation, despite GLP-1 retaining an insulin-releasing tration-dependent manner. GLP-1 similarly augmented the effect, demonstrating that GLP-1 can induce insulin release KATP channel-independent insulin-releasing effects of tolbuta- under conditions where sulphonylureas and nateglinide are no mide, glibenclamide or nateglinide. Downregulation of protein longer effective. Our results provide new insights into the kinase A (PKA)- or protein kinase C (PKC)-signalling pathways mechanisms of action of GLP-1, and further highlight the in culture revealed that the KATP channel-independent effects of promise of GLP-1 or similarly acting analogues alone or in sulphonylureas or nateglinide were critically dependent upon combination with sulphonylureas or meglitinide drugs in type 2 intact PKA and PKC signalling.
    [Show full text]
  • Optum Essential Health Benefits Enhanced Formulary PDL January
    PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES
    [Show full text]
  • Management of Chronic Problems
    MANAGEMENT OF CHRONIC PROBLEMS INTERACTIONS BETWEEN ALCOHOL AND DRUGS A. Leary,* T. MacDonald† SUMMARY concerned. Alcohol may alter the effects of the drug; drug In western society alcohol consumption is common as is may change the effects of alcohol; or both may occur. the use of therapeutic drugs. It is not surprising therefore The interaction between alcohol and drug may be that concomitant use of these should occur frequently. The pharmacokinetic, with altered absorption, metabolism or consequences of this combination vary with the dose of elimination of the drug, alcohol or both.2 Alcohol may drug, the amount of alcohol taken, the mode of affect drug pharmacokinetics by altering gastric emptying administration and the pharmacological effects of the drug or liver metabolism. Drugs may affect alcohol kinetics by concerned. Interactions may be pharmacokinetic or altering gastric emptying or inhibiting gastric alcohol pharmacodynamic, and while coincidental use of alcohol dehydrogenase (ADH).3 This may lead to altered tissue may affect the metabolism or action of a drug, a drug may concentrations of one or both agents, with resultant toxicity. equally affect the metabolism or action of alcohol. Alcohol- The results of concomitant use may also be principally drug interactions may differ with acute and chronic alcohol pharmacodynamic, with combined alcohol and drug effects ingestion, particularly where toxicity is due to a metabolite occurring at the receptor level without important changes rather than the parent drug. There is both inter- and intra- in plasma concentration of either. Some interactions have individual variation in the response to concomitant drug both kinetic and dynamic components and, where this is and alcohol use.
    [Show full text]
  • DESCRIPTION Tolazamide Is an Oral Blood-Glucose-Lowering Drug of the Sulfonylurea Class
    TOLAZAMIDE- tolazamide tablet PD-Rx Pharmaceuticals, Inc. ---------- DESCRIPTION Tolazamide is an oral blood-glucose-lowering drug of the sulfonylurea class. Tolazamide is a white or creamy-white powder very slightly soluble in water and slightly soluble in alcohol. The chemical name is 1-(Hexahydro-1 H-azepin-1-yl)-3-( p-tolylsulfonyl)urea. Tolazamide has the following structural formula: Each tablet for oral administration contains 250 mg or 500 mg of tolazamide, USP and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. CLINICAL PHARMACOLOGY Actions Tolazamide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which tolazamide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in type II diabetic patients, the blood glucose-lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. Some patients who are initially responsive to oral hypoglycemic drugs, including tolazamide tablets, may become unresponsive or poorly responsive over time. Alternatively, tolazamide tablets may be effective in some patients who have become unresponsive to one or more other sulfonylurea drugs. In addition to its blood glucose-lowering actions, tolazamide produces a mild diuresis by enhancement of renal free water clearance. Pharmacokinetics Tolazamide is rapidly and well absorbed from the gastrointestinal tract. Peak serum concentrations occur at 3 to 4 hours following a single oral dose of the drug.
    [Show full text]
  • Eslicarbazepine Acetate Longer Procedure No
    European Medicines Agency London, 19 February 2009 Doc. Ref.: EMEA/135697/2009 CHMP ASSESSMENT REPORT FOR authorised Exalief International Nonproprietary Name: eslicarbazepine acetate longer Procedure No. EMEA/H/C/000987 no Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. product Medicinal 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: [email protected] http://www.emea.europa.eu TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE........................................... 3 1.1. Submission of the dossier ...................................................................................................... 3 1.2. Steps taken for the assessment of the product..................................................................... 3 2. SCIENTIFIC DISCUSSION................................................................................................. 4 2.1. Introduction............................................................................................................................ 4 2.2. Quality aspects ....................................................................................................................... 5 2.3. Non-clinical aspects................................................................................................................ 8 2.4. Clinical aspects....................................................................................................................
    [Show full text]
  • Alcohol-Medication Interactions: the Acetaldehyde Syndrome
    arm Ph ac f ov l o i a g n il r a n u c o e J Journal of Pharmacovigilance Borja-Oliveira, J Pharmacovigilance 2014, 2:5 ISSN: 2329-6887 DOI: 10.4172/2329-6887.1000145 Review Article Open Access Alcohol-Medication Interactions: The Acetaldehyde Syndrome Caroline R Borja-Oliveira* University of São Paulo, School of Arts, Sciences and Humanities, São Paulo 03828-000, Brazil *Corresponding author: Caroline R Borja-Oliveira, University of São Paulo, School of Arts, Sciences and Humanities, Av. Arlindo Bettio, 1000, Ermelino Matarazzo, São Paulo 03828-000, Brazil, Tel: +55-11-30911027; E-mail: [email protected] Received date: August 21, 2014, Accepted date: September 11, 2014, Published date: September 20, 2014 Copyright: © 2014 Borja-Oliveira CR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Medications that inhibit aldehyde dehydrogenase when coadministered with alcohol produce accumulation of acetaldehyde. Acetaldehyde toxic effects are characterized by facial flushing, nausea, vomiting, tachycardia and hypotension, symptoms known as acetaldehyde syndrome, disulfiram-like reactions or antabuse effects. Severe and even fatal outcomes are reported. Besides the aversive drugs used in alcohol dependence disulfiram and cyanamide (carbimide), several other pharmaceutical agents are known to produce alcohol intolerance, such as certain anti-infectives, as cephalosporins, nitroimidazoles and furazolidone, dermatological preparations, as tacrolimus and pimecrolimus, as well as chlorpropamide and nilutamide. The reactions are also observed in some individuals after the simultaneous use of products containing alcohol and disulfiram-like reactions inducers.
    [Show full text]
  • Enhancement of Dissolution and Oral Bioavailability of Gliquidone with Hydroxy Propyl-Β-Cyclodextrin
    ORIGINAL ARTICLES Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad, India Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-b-cyclodextrin S. Sridevi, A. S. Chauhan, K. B. Chalasani, A. K. Jain, P. V. Diwan Received November 15, 2002, accepted May 5, 2003 Dr. Prakash V. Diwan, Pharmacology Division, Indian Institute of Chemical Technology, Hyderabad – 500 007 A.P., India [email protected] Pharmazie 58: 807–810 (2003) The virtual insolubility of gliquidone in water results in poor wettability and dissolution characteristics, which may lead to a variation in bioavailability. To improve these characteristics of gliquidone, binary systems with hydroxypropyl-b-cyclodextrin (HP-b-CD) were prepared by classical methods such as physical mixing, kneading, co-evaporation and co-lyophilization. The solid state interaction between the drug and HP-b-CD was assessed by evaluating the binary systems with X-ray diffraction, differen- tial scanning calorimetry and IR- spectroscopy. The results establish the molecular encapsulation and amorphization of gliquidone. The phase solubility profile of gliquidone in aqueous HP-b-CD vehicle À1 resulted in an AL type curve with a stability constant of 1625 M . The dissolution rate of binary sys- tems was greater than that of pure drug and was significantly higher in the case of co-lyophilized and co-evaporated systems. Upon oral administration, [AUC]0-a was significantly higher in case of co-lyo- philized (2 times) and co-evaporated systems (1.5 times) compared to pure drug suspension while other binary systems showed only a marginal improvement. The study ascertained the utility of HP-b- CD in enhancing the oral bioavailability of gliquidone, and points towards a strong influence of the preparation method on the physicochemical properties.
    [Show full text]
  • Sulfonylurea Review
    Human Journals Review Article February 2018 Vol.:11, Issue:3 © All rights are reserved by Farah Yousef et al. Sulfonylurea Review Keywords: Type II diabetes, Sulfonylurea, Glimipiride, Glybu- ride, Structure Activity Relationship. ABSTRACT Farah Yousef*1, Oussama Mansour2, Jehad Herbali3 Diabetes Mellitus is a chronic disease represented with high 1 Ph.D. candidate in pharmaceutical sciences, Damas- glucose blood levels. Although sulfonylurea compounds are the cus University, Damascus, Syria. second preferred drug to treat Type II Diabetes (TYIID), they are still the most used agents due to their lower cost and as a 2 Assistant Professor in pharmaceutical chimestry, Ti- mono-dosing. Literature divides these compounds according to st nd rd shreen University, Lattakia, Syria their discovery into 1 , 2 , 3 generations. However, only six sulfonylurea compounds are now available for use in the United 3 Assistant Professor in pharmaceutical chimestry, Da- States: Chlorpropamide, Glimepiride, Glipizide, Glyburide, mascus University, Damascus, Syria. Tolazamide, and Tolbutamide. They function by increasing Submission: 24 January 2018 insulin secretion from pancreatic beta cells. Their main active site is ATP sensitive potassium ion channels; Kir 6.2\SUR1; Accepted: 29 January 2018 Published: 28 February 2018 Potassium Inward Rectifier ion channel 6.2\ Sulfonylurea re- ceptor 1. They are sulfonamide derivatives. However, research- ers have declared that sulfonylurea moiety is not the only one responsible for this group efficacy. It has been known that sud- den and acute hypoglycemia incidences and weight gain are the www.ijppr.humanjournals.com two most common adverse effects TYIID the patient might face during treatment with sulfonylurea agents. This review indi- cates the historical development of sulfonylurea and the differ- ences among this group members.
    [Show full text]
  • Sulfonylureas
    Therapeutic Class Overview Sulfonylureas INTRODUCTION In the United States (US), diabetes mellitus affects more than 30 million people and is the 7th leading cause of death (Centers for Disease Control and Prevention [CDC] 2018). Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is characterized by elevated fasting and postprandial glucose concentrations (American Diabetes Association [ADA] 2019[a]). It is a chronic illness that requires continuing medical care and ongoing patient self-management education and support to prevent acute complications and to reduce the risk of long-term complications (ADA 2019[b]). ○ Complications of T2DM include hypertension, heart disease, stroke, vision loss, nephropathy, and neuropathy (ADA 2019[a]). In addition to dietary and lifestyle management, T2DM can be treated with insulin, one or more oral medications, or a combination of both. Many patients with T2DM will require combination therapy (Garber et al 2019). Classes of oral medications for the management of blood glucose levels in patients with T2DM focus on increasing insulin secretion, increasing insulin responsiveness, or both, decreasing the rate of carbohydrate absorption, decreasing the rate of hepatic glucose production, decreasing the rate of glucagon secretion, and blocking glucose reabsorption by the kidney (Garber et al 2019). Pharmacologic options for T2DM include sulfonylureas (SFUs), biguanides, thiazolidinediones (TZDs), meglitinides, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, amylinomimetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors, combination products, and insulin (Garber et al 2019). SFUs are the oldest of the oral antidiabetic medications, and all agents are available generically. The SFUs can be divided into 2 categories: first-generation and second-generation.
    [Show full text]
  • Flufenamic Acid # # Keke Zhang, Noalle Fellah, Vilmalí Lopez-Mej́ Ías, and Michael D
    pubs.acs.org/crystal Communication Polymorphic Phase Transformation Pathways under Nanoconfinement: Flufenamic Acid # # Keke Zhang, Noalle Fellah, Vilmalí Lopez-Mej́ ías, and Michael D. Ward* Cite This: Cryst. Growth Des. 2020, 20, 7098−7103 Read Online ACCESS Metrics & More Article Recommendations *sı Supporting Information ABSTRACT: Flufenamic acid (FFA) is a highly polymorphic com- pound, with nine forms to date. When melt crystallization was performed under nanoscale confinement in controlled pore glass (CPG), the formation of the extremely unstable FFA form VIII was favored. Under confinement, form VIII was sufficiently stable to allow the measurement of its melting point, which decreased with decreasing pore size in accord with the Gibbs−Thomson relationship, enabling determination of the otherwise elusive melting point of the bulk form. Moreover, the transformation pathways among the various polymorphs depended on pore size, proceeding as form VIII → form II → form I for nanocrystals embedded in 30−50-nm diameter pores, and form VIII → form IV → form III in 100−200 nm pores. In contrast, form VIII converts directly to form III in the bulk. Whereas previous reports have demonstrated that nanoconfinement can alter (thermodynamic) polymorph stability rankings, these results illustrate that nanoscale confinement can arrest and alter phase transformations kinetics such that otherwise hidden pathways can be observed. olymorphism in solid-state materials can be a double- intersect.11 This has been most apparent in the observation P edged sword.
    [Show full text]
  • International Journal of Pharmacy Teaching & Practices (IJPTP)
    Vol 5, Issue 3 Supplement 2014 International Journal of Pharmacy Teaching & Practices (IJPTP) Clinical Case Reports - September, 2014 Published by: DRUNPP Association of Sarajevo, Bosnia & Herzegovinia www.iomcworld.com/ijptp email: [email protected] ISSN: 1986-8111 International Journal of Pharmacy Teaching & Practices, Vol5, issue3, Supplement I, 1020-1552. EDITORIAL BOARD Editor-in-Chief Dr. Syed Wasif Gillani Associate Prof. Dr. Azmi Sarriff Editorial Assistant Dr. Mostafa Nejati Executive Editors Prof. Dr. Syed Azhar Syed Sulaiman Dr. Waffa Mohamed El-Anor Ahmed Rashed Prof. Dr. Mark Raymond Mr. Robert Hougland Advisory Board Members Dr. Mensurak Kudumovic Dr. Jasmin Musanovic Dr. Monica Gaidhane Assoc.Prof. Dr. Mok.T Chong Dr. Syed Tajuddin Syed Hassan Dr. Sumeet Dwivedi Dr. Dibyajyoti saha EDITORIAL ADDRESS: KA311, KEYANGANG, BANDAR SUNWAY, SELANGOR, MALAYSIA PUBLISHED BY: DRUNPP, SARAJEVO, BOLNICKA BB. VOLUME 5, ISSUE 3, SUPP I, 2014 ISSN: 1986-8111, INDEXED ON: EBSCO PUBLISHING (EP)USA, INDEX COPERNICUS (IC) POLAND 1020 International Journal of Pharmacy Teaching & Practices, Vol5, issue3, Supplement I, 1020-1552. Table of Contents 1. ISCHIALGIA AND LUNG TUMOR IN MINTOHARDJO HOSPITAL ............................................................ 1026 2. THE MONITORING OF DRUG THERAPY FOR CRF (Chronic Renal Failure) PATIENT IN Dr. MINTOHARDJO, INDONESIAN NAVY MILITARY HOSPITAL.............................................................................................. 1031 3. DIABETES MELLITUS TYPE II, and CHRONIC RENAL FAILURE
    [Show full text]